B/F/TAF + Atripla + B/F/TAF Placebo + Atripla Placebo
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection
Trial Timeline
Oct 29, 2018 → Sep 3, 2020
NCT ID
NCT03532425About B/F/TAF + Atripla + B/F/TAF Placebo + Atripla Placebo
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla Placebo is a approved stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT03532425. Target conditions include HIV-1-infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03532425 | Approved | Terminated |
Competing Products
20 competing products in HIV-1-infection